Resolving the mRNA Encapsulation‐Release Trade‐off via Compensatory Forces in Engineered Ionizable Lipids
Advanced Materials · 2025
DOI: 10.1002/adma.202512235 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2025. Verfasst von Weixiang Gao und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, P…. Hauptthemen laut MEDLINE: RNA, Messenger, Lipids. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Distinguished Young Scholars Program, National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
A critical challenge in lipid nanoparticle (LNP) delivery of messenger RNA (mRNA) is the inherent trade‐off between stable encapsulation and efficient intracellular release. Here, this challenge is addressed through rationally engineering compensatory forces between mRNA and LNP, leveraging short‐range intermolecular interactions (van der Waals, hydrogen bonding) to dynamically balance long‐range Coulombic binding. Guided by a computational‐experimental framework, a “contact number” metric is developed to decipher mRNA and LNP binding hierarchies, enabling the strategic incorporation of short‐range‐interaction motifs (e.g., urea, carbamate) into ionizable lipid (IL) structures. These designs achieve optimal mRNA encapsulation while promoting endosomal escape and cytosolic release, resulting in enhanced mRNA translation. Compared to commercial mRNA vaccine counterparts, the engineered LNP (OT13‐LNP) induces a 1.7‐fold increase in antigen‐specific T cell responses and 77.9% tumor inhibition in melanoma. In hepatic gene editing, OT13‐LNPs achieve comparable transthyretin (TTR) on‐target editing efficiency to ALC0315‐LNPs (0.5 mg kg −1 ), but elicit a markedly stronger silencing effect, reducing serum TTR levels by over 90% compared with ≈58% for ALC0315‐LNPs. This study may highlights the potential of compensatory‐force engineering for next‐generation mRNA therapeutics in oncology, gene editing, and infectious diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
- University of Chinese Academy of Sciences, Beijing, 100049, P. R. China.
- XJTLU Wisdom Lake Academy of Pharmacy, Xi'an Jiaotong-Liverpool University, Suzhou, Jiangsu, 215123, P. R. China.
- Epigenic Therapeutics, Inc, Shanghai, 200135, P. R. China.
- Institute of Neuroscience, Chinese Academy of Sciences, Shanghai, P. R. China.
ORCID-Profile: Yufei Xia
Förderung
- Distinguished Young Scholars Program
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Chinese Academy of Sciences
- Frontier Basic Research
Zitieren
APA
Gao, W., An, K., Ma, Y., Xu, X., Wang, Z., Liu, J., Shan, X., Liu, Y., Chen, W., Wang, P., Zhou, C., Ren, Y., Huang, X., & Xia, Y. (2025). Resolving the mRNA Encapsulation‐Release Trade‐off via Compensatory Forces in Engineered Ionizable Lipids. Advanced Materials. https://doi.org/10.1002/adma.202512235
Vancouver
Gao W, An K, Ma Y, Xu X, Wang Z, Liu J, et al. Resolving the mRNA Encapsulation‐Release Trade‐off via Compensatory Forces in Engineered Ionizable Lipids. Advanced Materials. 2025. doi:10.1002/adma.202512235
BibTeX
@article{Gao2025,
author = {Gao, Weixiang and An, Kang and Ma, Yishan and Xu, Xiao and Wang, Ziyue and Liu, Junjian and Shan, Xiangfei and Liu, Yuqi and Chen, Wei and Wang, Peicheng and Zhou, Changyang and Ren, Ying and Huang, Xiaonan and Xia, Yufei},
title = {Resolving the mRNA Encapsulation‐Release Trade‐off via Compensatory Forces in Engineered Ionizable Lipids},
journal = {Advanced Materials},
year = {2025},
doi = {10.1002/adma.202512235}
}
EUVIMED